Ratliff John D 4

4 · LABORATORY CORP OF AMERICA HOLDINGS · Filed Feb 14, 2019

Form 4

Period: 2019-02-12

CEO, Covance Drug Development

Transactions

Exercise/Conversion
Common Stock
2019-02-12+1,463→ 16,255 total
Tax Payment
Common Stock
2019-02-12$146.59/sh−654$95,870→ 15,601 total
Exercise/Conversion
Restricted Stock Unit
2019-02-12−1,463→ 16,911 total
→ Common Stock (1,463 underlying)
Award
Restricted Stock Unit
2019-02-12+5,300→ 22,211 total
→ Common Stock (5,300 underlying)
Award
Non-qualified Stock Options
2019-02-12+21,800→ 21,800 total
Exercise: $146.59From: 2020-02-12Exp: 2029-02-11→ Common Stock (21,800 underlying)

Holdings

Footnotes (8)

[F1]Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
[F2]Stock withholding to satisfy tax withholding obligations.
[F3]The reporting person is not a trustee of the irrevocable trust and disclaims beneficial ownership of the shares.
[F4]The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on 2/12/19.
[F5]This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
[F6]The Restricted Stock Units vest in three equal annual installments beginning on 2/12/2020.
[F7]Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
[F8]The option vests in three equal installments beginning on the date reflected in this column.

Documents

1 file